Please ensure Javascript is enabled for purposes of website accessibility

Why Intersect ENT Shares Are Crashing 31.6% Today

By Todd Campbell - May 6, 2016 at 12:31PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Concern over personnel turnover and decelerating growth may be weighing on shares.

Image source: Intersect ENT.

What: After Intersect ENT (XENT) reported first-quarter financials after the closing bell yesterday that failed to spark investor optimism, its shares tumbled 31.6% at 11:30 a.m. ET today.  

So what: Intersect ENT markets the steroid-releasing implants Propel and Propel mini for use in improving outcomes for chronic sinusitis patients who undergo sinus surgery. 

Last quarter, management reported that sales grew 24.8% year over year to $16.7 million. That was a couple hundred thousand dollars less than industry watchers had projected. It also said it lost $0.29 per share in Q1, which was in line with expectations. Additionally, it noted that first-quarter gross margin ticked up 2% year over year, to 81%.

On the surface, that doesn't look like a bad quarter. However, in the Q&A session during the company's conference call, it's evident that there is ongoing concern among investors regarding a deceleration in top-line growth rates and personnel turnover in its sales team.

XENT Revenue (Quarterly YoY Growth) Chart

XENT Revenue (Quarterly YYY Growth) data by YCharts

Now what: The company has been shuffling around its sales team, including redefining territories, and it's lost some sales members and replaced others. Coupled with the turnover, the pace of growth for Intersect ENT has suffered.

Even so, Intersect ENT is still guiding for revenue in the range of $78 million to $80 million this year and for gross margins of between 80% to 81%. The company's operating expense will be about $92 million, and cash burn will be approximately $25 million for the year. 

Regardless, questions remain about its growth trajectory, and that probably warrants taking a wait-and-see approach to this stock. Therefore, I'm content to see how the next few quarters play out before considering this for portfolios.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Intersect ENT, Inc. Stock Quote
Intersect ENT, Inc.
XENT

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.